Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Abstract

Abstract A common and challenging side effect associated with CAR-T cell therapy is immune cell-associated neurotoxicity syndrome (ICANS), which occurs in 20–60% of patients, of whom 12–30% have severe (≥ grade 3) symptoms.

Topics & Concepts